• Leptin;
  • obesity;
  • recombinant methionyl human leptin


  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References

Leptin is a pleiotropic cytokine-like hormone that is involved in the regulation of energy intake and expenditure, neuroendocrine function, immunity and lipid and glucose metabolism. The few humans with genetically based leptin deficiency provide a unique model to assess those effects. We have identified five Turkish patients (one male and two female adults; one boy and one girl) with congenital leptin deficiency due to a missense mutation in the leptin gene. Four of these patients were treated with physiological doses of recombinant methionyl human leptin. Body composition, brain structure and function, behaviour, immunity and endocrine and metabolic parameters were evaluated before and during treatment. Our results showed that leptin has peripheral, hypothalamic and extra-hypothalamic effects. Within the endocrine system, leptin regulates the circadian rhythms of cortisol, thyroid-stimulating hormone, luteinizing hormone and follicle-stimulating hormone. In the brain, leptin controls energy balance and body weight, and plays a role on neurogenesis and brain function. Leptin is a key element of the adiposinsular axis, enhances immune response, and regulates inflammation, coagulation, fibrinolysis and platelet aggregation. Our 10-year experience in treating these unique patients provided valuable data on the peripheral and central effects of leptin. Those results can be taken into account for the development of leptin-based therapies for other diseases.


  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References

At the end of the 20th century we witnessed the dawn of adipokines: cytokine-like hormones produced by the adipose tissue, which regulate systemic processes, such as food intake and energy metabolism, insulin sensitivity, reproduction, stress responses, bone growth and inflammation. The list of adipokines continues to grow and leptin is at the top of this list, as the first identified adipokine, discovered by positional cloning in 1994 (1). Since then, the adipose tissue has acquired the status of a metabolically active endocrine organ.

Animal models with spontaneous mutations in the leptin gene and in the leptin receptor existed for decades before the identification of the substance responsible for the phenotype of these animals (2,3). Leptin-deficient mice present low or undetectable leptin levels. Phenotypically, they are hyperphagic, have lower resting energy expenditure and are less active, leading to a severe form of obesity (4). Many alterations in the endocrine system are observed, such as hypogonadotrophic hypogonadism (5), hyperinsulinemia and insulin resistance (6), elevated levels of corticosterone, decreased growth hormone levels and hypothalamic hypothyroidism (7). Other alterations include cellular immune defects (8), cardiac and sympathetic tone dysfunctions (9), and increased bone formation and bone density (10). Through parabiosis studies, it has been determined that the in the leptin-deficient ob/ob mice lack from a factor that is produced by the leptin-resistant db/db(11,12).

The identification and characterization of leptin and the effects of its absence and replacement in mice paved the way for the identification of leptin-deficient humans who were first described in 1997 (13). Since then, a total of 20 patients with congenital leptin deficiency due to distinct mutations in the leptin gene have been identified in patients of Pakistani (n = 12) (13–15), Turkish (n = 5) (16–18), Egyptian (n = 2) (19) and Austrian (n = 1) (20) backgrounds. One of the Turkish patients (Patient E, Fig. 1) died of sepsis due to immune defects before the initiation of leptin replacement therapy with recombinant methionyl human leptin (Amylin Pharmaceuticals, San Diego, CA, USA) (21). As four of the Pakistani and seven undiagnosed Turkish patients also died of sepsis during childhood (21), the mortality rate among leptin-deficient patients is at least 20%. Most of the remaining patients are currently on leptin replacement therapy, with remarkable effects on body composition, endocrine parameters, immunity and brain structure and function.


Figure 1. Pedigree chart showing individuals homozygous and heterozygous for the leptin gene mutation. Patient A: 22-year-old adult man; patient B: 34-year-old adult woman; patient C: 30-year-old adult woman; patient D: 5-year-old boy; patient E: 6-year-old girl (all ages at diagnosis).

Download figure to PowerPoint

This review will focus on the phenotypic findings in leptin-deficient humans, before and after the initiation of leptin replacement therapy. In particular, the results of the 10th year of leptin replacement in the Turkish cohort will be discussed in detail.

Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds

  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References

In 1997, the first two children with congenital leptin deficiency due to a mutation in the leptin gene were identified (13). Those children were from a highly consanguineous Pakistani family, and presented with a phenotype similar to that of the ob/ob mouse: hyperphagia and impaired satiety leading to early severe obesity, hyperinsulinemia and very low levels of serum leptin. However, these children did not have elevated levels of corticosteroids, impaired linear growth, hyperglycaemia or hypothalamic hypothyroidism. In addition, their bone mineral densities were normal (14). Genetic analysis showed a homozygous frame-shift mutation involving the deletion of a single guanine nucleotide in codon 133 of the leptin gene (ΔG133), in both patients. Subsequently, another child from the same pedigree with a similar phenotype and the same mutation was identified (14). A few years later, another child of Pakistani background and with the same mutation, but from a different pedigree, was identified. Her phenotype was similar, with the addition of primary subclinical hypothyroidism (15). Other patients of Pakistani origin were also identified by the same group, totalling seven individuals with congenital leptin deficiency due to the same frame-shift homozygous mutation in the leptin gene (22).

More recently, an N103K substitution has been reported in a severely hyperphagic and obese Egyptian boy, who also was hyperinsulinemic. In this patient, a glycogen storage disease (as an independent disease, or secondary to leptin deficiency) was also suspected due to episodes of hypoglycaemia and to the findings of a liver biopsy. His 7-year-old sister also had an obese phenotype and was homozygous for the same mutation (19). Finally, a L72S mutation was diagnosed in an Austrian female teenager with a milder form of obesity (possibly to a voluntary restriction of caloric intake) and normal T-cell responsiveness. This patient also had dyslipidemia, hyperinsulinemia, low levels of free T4 and normal levels of thyroid-stimulating hormone (TSH, suggestive of central hypothyroidism), and hypogonadotropic hypogonadism, even though she had had spontaneous onset of puberty (20).

Treatment of the Pakistani children with a subcutaneous daily injection of r-metHuLeptin led to a decrease in food intake, which resulted in significant weight loss at the expense of a decrease in fat mass. No changes in basal metabolic rate, free-living energy expenditure or total energy expenditure were observed. With weight loss, insulin and lipid levels changed towards normal levels. Thyroid function tests were normal before treatment in three patients, with an increase in free T4 after leptin was initiated. In the fourth patient, hypothyroidism was reversed. The older child entered puberty at age 12. In addition, leptin replacement increased the previously impaired T-cell responsiveness, by increasing the number of CD4+ naive T-cells and by restoring interferon-gamma (IFN-γ) secretion, and the predominant Th2 cytokine response was switched to a Th1 response with leptin administration (14,15,23).

Leptin deficiency in Turkish patients

  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References

Although some of the aforementioned patients of Pakistani background have now reached adulthood, they have all started leptin replacement during childhood. Therefore, the effects of leptin deficiency in human adults who underwent their entire childhood and puberty without leptin were unknown. In 1998, the first leptin-deficient adults in the world were reported (18). Due to a severe obese phenotype (body mass index [BMI] of 55.8 kg m−2) and hypogonadotropic hypogonadism, a 22-year-old adult man (patient A) entering the Turkish mandatory military service was suspected as being leptin-deficient. Extremely low serum leptin levels (0.9 ng mL−1) were found not only in this patient, but also in another 34-year-old adult woman (patient B (1.6 ng mL−1) and in a 6-year-old girl (1.1 ng mL−1) from the same family, who were also morbidly obese and hypogonadal (the adult woman). Subsequently, a 30-year-old woman (patient C) and a 5-year-old boy (patient D) from the same pedigree were diagnosed as leptin-deficient (17,21) (Fig. 1). The leptin-deficient girl (patient E) died of sepsis at age 9, before the initiation of leptin replacement, possibly due to immune defects related to leptin deficiency. Our group has been studying these unique patients since 1998, and the effects of leptin replacement have been evaluated for 10 years. In this review, we summarize the findings from previous studies, which were all approved by the local Ethics Committees at various institutions. For all of the studies, the patients signed informed consents.

Those patients were homozygous for a C[RIGHTWARDS ARROW]T substitution in codon 105 of the leptin gene, resulting in an Arg[RIGHTWARDS ARROW]Trp replacement in the mature protein. This mutation leads to the synthesis of a protein that is abnormally processed during its secretory pathway, and that is not secreted into the medium. It is the same mutation that is observed in ob/ob mice. However, in animals, the C[RIGHTWARDS ARROW]T substitution in codon 105 leads to premature stop codon. This mutation is easily detected by PCR because the substitution abolishes an MspI restriction site (18).

Treatment with recombinant methionyl human leptin was initiated at ages 5 (boy), 27 (adult man), 30 and 40 (women). Doses started at 0.02–0.04 mg kg−1 d−1 at 6 pm and were designed to achieve a normal leptin concentration based on a body fat of 30% in adult women and 20% in adult men. The child's dose was initially calculated to achieve a peak serum leptin concentration of 70 ng mL−1, which is equivalent to 10% of the child's predicted normal serum leptin concentration (based on age, sex and body composition) (24,25). Subsequently, doses were decreased as patients lost weight to avoid excessively rapid weight loss. We chose a daily subcutaneous injection in the evening in order to mimic leptin's circadian rhythm, of which the peak occurs at night (26).

During this prolonged follow-up, minimum dose adjustments were made, based on clinical grounds (mainly weight gain or excessive loss). The adults' initial mean dose was 4.1 ± 1.2 mg d−1 (2.8 mg for the man, 4.2 mg for the younger woman and 5.3 mg for the older woman), and the current dose is 1.4 ± 1.9 mg d−1 (0.3 mg for the man, 0.45 mg for the younger woman and 3.6 mg for the older woman). The child's initial dose was 1.36 mg d−1, and the current dose is 0.95 mg. Significant dose decreases were possible for the man and for the younger woman. However, the older woman is on a considerably higher dose on leptin. Besides being the oldest patient, she is the most obese and was diagnosed with type 2 diabetes before treatment. Therefore, it is possible that this patient also presents common obesity as an underlying disease and therefore leptin resistance. The child is on a higher dose, as compared to the man and the younger woman. Decreases in dose led to weight gain and to growth deceleration (from the 50th to the 10th percentile of the growth curve, over 2 years). As dose was increased, the child is now between the 10th and the 25th percentile, and will likely achieve his targeted stature (Fig. 2).


Figure 2. Patient D's growth chart. In the last evaluation, the patient gained 4 kg over 45 d. During that period, doses were decreased to one-third of the original dose due to a temporary shortage of drug supply.

Download figure to PowerPoint

Body composition, food intake and energy expenditure

Phenotypically, all of the patients were morbidly obese. With treatment, the adults' mean BMI decreased from 51.2 ± 2.5 kg m−2 to 26.9 ± 2.1 kg m−2 after 18 months of treatment. At the eighth year of treatment, the mean BMI was 29.5 ± 3.4 kg m−2. The patients' BMIs most likely reflect those of commonly obese or overweight non-leptin deficient humans, and not incomplete dosing of recombinant methionyl human leptin. Patients A and B complained of excessive anorexia when higher doses were given, and Patient C is already taking the maximum physiological dose that determines normal leptin levels. Over the course of treatment, weight was fairly stable, except for clinically advised and closely monitored periods of leptin withdrawal in the adults. During those periods, leptin replacement was withdrawn for up to 6 weeks, making the patients gain from 6 to 10 kg. At the 10th year, after a temporary leptin withdrawal, mean BMI was 33.1 ± 5.3 kg m−2. Weight promptly returned to pre-withdrawal levels after leptin was reintroduced. The child's BMI decreased from 39.6 kg m−2 to 24.4 kg m−2.

The decrease in BMI occurred mainly due to fat mass loss, and at a smaller extent, to lean mass loss, as measured by dual energy X-ray absorptiometry (16). After 18 months of leptin replacement, the absolute fat mass decreased from 62.5 kg to 9.5 kg in Patient A, from 54.9 kg to 16.8 kg in Patient B and from 68.4 kg to 28.3 kg in Patient C. Relative to total body weight, total body fat decreased from 46.6% to 14.8% in Patient A, from 50.6% to 27.8% in Patient B and from 51.7% to 38.1% in Patient C. In addition, the total lean mass decreased from 71.6 kg to 54.8 kg in Patient A (24% of total weight loss), from 53.5 kg to 43.6 kg in Patient B (21% of total weight loss) and from 64.0 kg to 46.0 kg in Patient C (31% of total weight loss). Since the fat mass decreased at a larger extent, the lean mass relative to total body weight increased in all patients (from 53.4% to 85.3% in Patient A, from 49.3% to 72.1% in Patient B and from 48.3% to 61.9% in Patient C). At baseline and after 18 months, the women's measured fat masses were close to the predicted fat masses according to their total body weights. The man's fat mass was 33% above the predicted mass before treatment, and decreased to levels close to the predicted after 18 months (27).

In the first month of treatment food intake markedly decreased in all adult patients, from 2384 ± 946 kcal d−1 to 1179 ± 790 kcal d−1. Subsequently, caloric intake increased and stabilized at approximately 1907 ±  739 kcal d−1 (as measured 7 years after treatment). In the first 6 months, the decrease in caloric intake resulted in a temporary increase of fat intake and in a decrease in carbohydrate intake, both relatively to the total caloric intake. That was reversed after 12 months, with an increase in carbohydrate and a decrease in fat consumption (28). In the younger woman, leptin withdrawal for 2 weeks did not change the proportion of fat, carbohydrate and protein in the daily diet, but did decrease the intake of vitamin C, pyridoxine, pantothenic acid, folate, potassium, magnesium, copper, chromium, threonine, lysine, histidine, tryptophan, methionine and cystine (29). In the child, after 2 years, caloric intake also decreased from 2709 ± 370 to 2194 ± 292 kcal d−1, which is 106% of the recommended caloric intake for a boy this age, height and weight (17).

The observed alterations in food intake resulted from changes in the motivation to eat. After 15 weeks, leptin replacement reduced overall food consumption, rate of eating and duration of eating at each course of every meal. Leptin slowed the rate of eating and reduced the time spent eating each food item. In addition, patients reported markedly less hunger, less desire to eat and greater fullness, both before and after the meals. After receiving leptin, participants found the foods to be equally appealing in taste, texture, aroma and the filling qualities (30).

Activity levels, measured by actigraphy, also increased with leptin replacement (16). At baseline, the three adults had 24-h energy expenditure and 24-h fat oxidation similar to those of normal controls. After treatment, energy expenditure was still normal, and its decrease associated with weight loss was less pronounced in the leptin-deficient subjects than that of controls under a weight loss programme. Similarly, fat oxidation was also higher in the treated leptin-deficient patients. These results show that leptin does not increase absolute energy expenditure, but it does prevent the weight loss-induced reduction in metabolic rate (31).

Bone mineral density was normal in all patients, except for the adult man, who had low bone mineral density of the spine (bone mineral density of L2–L4, 0.924 g cm−2; T-score −1.96; Z-score −2.36) (21). These changes in bone mineral density are in contradiction to those that are observed in ob/ob mice, and are more likely to be explained by the hypogonadism, rather than leptin deficiency. At baseline, parathyroid hormone levels were above reference values for all women (21). Later on, we identified low levels of 25-hydroxyvitamin D in these patients. We assume that they had secondary hyperparathyroidism due to low sun exposure, but we cannot exclude a direct effect of the absence of leptin on the vitamin D metabolism.

Lipids and glucose metabolism

Before treatment, all patients were hyperinsulinemic and dyslipidemic (low high-density lipoprotein cholesterol and normal-high or high triglycerides). The older woman had hyperglycaemia and was diagnosed with type 2 diabetes, which onset had probably occurred before the diagnosis of leptin deficiency (16,21). Leptin replacement normalized serum lipids, insulin and glucose levels, leading to the resolution of type 2 diabetes in the oldest patient (16).

The male adult was submitted to meal tolerance tests before and 1 week, 18 months and 24 months after leptin replacement was initiated. During each test, blood was collected every 7 min during 24 h for measurements of glucose, insulin and C-peptide. Deconvolution of C-peptide, modified insulin kinetics models and minimal glucose models were employed to determine insulin secretion, hepatic extraction and sensitivity, respectively. After 1 week, leptin replacement increased insulin hepatic extraction by 2.4-fold (resulting in a 1.8-fold decrease of posthepatic insulin delivery), without significant changes in insulin secretion, and also increased insulin sensitivity by 10%. After 24 months, we showed that leptin replacement increases insulin by at least 10-fold, with additional decreases in insulin secretion and hepatic extraction (32).

Paradoxically, after leptin withdrawal, insulin sensitivity further increased, as measured by euglycaemic hyperinsulinemic clamps (33). However, we hypothesize that this increase in insulin sensitivity is attributed to the quick gain in glucose-absorbing fat mass following leptin withdrawal. This increase in insulin sensitivity when off leptin was clinically evident when the adult man developed severe hypoglycaemia during an oral glucose tolerance test.

During euglycaemic hyperinsulinemic clamps, we showed that the levels of nonesterified fatty acids are decreased by hyperinsulinemia due to insulin's stimulatory effects on lipogenesis and inhibitory actions on lipolysis. After leptin withdrawal, this decrease in nonesterified fatty acids was further enhanced, showing that leptin counteracts insulin's effects on lipogenesis and lipolysis (34).

Gonadal and reproductive function

Hypogonadotropic hypogonadism was observed in all of the adults, with normal gonadotropin responses to GnRH stimulation. The adult man had no signs of puberty – no beard, scanty hair in the pubic and axillary areas, bilateral gynecomastia, small penis, small testis size and azoospermia. His baseline measurements of testosterone and free testosterone were below the normal range for his age. The older woman had had spontaneous menarche at age 35, and had scarce hair in the pubic and axillary areas, no mammary tissue and small uterus and ovaries. The younger woman had spontaneous menarche at age 29, with normal hair in the pubic and axillary areas, diminished mammary tissue and small ovaries and borderline uterus. Both women had a luteal phase defect with low midluteal phase progesterone levels (21). The spontaneous onset of puberty shows that leptin is important (35), but not obligatory for the start of puberty in female humans.

Menstrual periods became regular after leptin replacement in both patients, with serial midluteal phase progesterone measurements >10 ng mL−1, which are indicative of ovulation. The adult man's testosterone and free testosterone levels reached normal values for adults, and the mean levels of luteinizing hormone (LH) and testosterone, measured over a 24-h period, also increased from 0.75 ± 0.04 mU mL−1 and 2.61 ±  0.06 ng mL−1 to 2.75 ± 0.07 mU mL−1 and 7.50 ± 0.07 ng mL−1, respectively. There were no changes in the number of pulses of LH and testosterone, but there was an increase in their amplitude. All patients fully developed secondary sexual characteristics (16).

Adrenal, sympathetic tone and biomarkers of cardiovascular disease

Although it has been shown that leptin concentrations are inversely related to adrenocorticotropic hormone (ACTH) and cortisol and modulate the levels of endogenous cortisol in healthy humans (26), hypercortisolemia was not observed in our patients. Levels of free urinary cortisol were normal, and were suppressed with 1 mg of dexamethasone (21). In the adult man, treatment increased the mean levels of serum cortisol measured over 24 h, from 4.04 ± 0.22 µg dL−1 to 5.97 ± 0.30 µg dL−1, with fewer pulses (25 vs. 19) of greater amplitude, greater morning rise and increased pattern regularity (16).

Low sympathetic tone was shown in the adults and in the girl, evaluated by cold pressor response tests, by orthostatic hypotension tests and by skin response tests. Sympathetic function was normal in heterozygous and wild-type subjects. When compared to 15 age- and sex-matched healthy subjects, systolic and diastolic cold pressor responses were significantly lower in the leptin-deficient patients (z = −4.7; P < 0.001 for both systolic and diastolic responses) (21).

The changes in biomarkers of inflammation, coagulation, fibrinolysis and platelet aggregation did not follow a pattern after leptin replacement. However, leptin withdrawal determined changes in most of these biomarkers towards a decreased state of thrombogenesis and increased fibrinolysis (36). This suggests that the absence of leptin may protect against cardiovascular diseases, even in a morbidly obese state.

Somatotropic axis

Growth hormone (GH) responses to both insulin-induced hypoglycaemia and exercise tests were absent in the man and in the younger adult woman, even though heights were normal. This blunted response is likely to be attributed to obesity (21). All of the insulin-like growth factor (IGF)-related parameters were within the normal range, except the postprandial insulin-like growth factor binding protein (IGFBP1), which was below the lower limit of normal (16). After 2 and 18 months of leptin replacement therapy, significant increases in IGFBP1 levels at the 18th month, both while fasting (21.1 ± 1.3 at baseline, 30.8 ± 7.1 at the second month, 140 ± 42 at the 18th month; reference range 13–120 ng mL−1; P = 0.02) and postprandial (3.7 ±  0.5 at baseline, 8.6 ± 1.9 at the second month, 18.1 ± 2.6 at the 18th month; reference range 10–30 ng mL−1; P = 0.0001). We also observed significant increases in mean insulin-like growth factor binding protein (IGFBP2), from 528 ± 54 to 936 ± 53 ng mL−1 at the 18th month, P < 0.001 (16). These changes are possibly attributed to the decrease in insulin levels (37).

Thyroid function

Thyroid function tests were normal for the adults. However, the girl had elevated TSH levels, with negative titres of antithyroid antibodies and normal free T4 and T3. Her response to thyrotropin-releasing hormone (TRH) was exaggerated, reflecting primary hypothyroidism (21). The 5-year-old boy had normal thyroid function tests (17), showing that the thyroid phenotype is heterogeneous in leptin deficiency (38). Changes in thyroid hormones have also been observed in the patients of Pakistani (15) and Austrian backgrounds (20), and the changes in thyroid function may be attributed to the lack of leptin. Leptin replacement did not increase free T4 or T3 (38), as previously observed in other studies (15). We have first demonstrated that leptin has a highly organized and distinct diurnal and circadian rhythm (26), which has a synchronous pattern with TSH (39). In healthy Caucasians, the rhythms of leptin and TSH were synchronized, with a nadir in late morning and a peak in the early morning hours. Heterozygous subjects showed a significant correlation between leptin and TSH rhythmicity, although weaker. Contrarily, the leptin-deficient adult man presented dysregulated patterns of TSH pulsatile and circadian rhythms.

Those data suggest that leptin has a role in regulating TSH secretion in humans, and its absence may lead to thyroid dysfunction. However, it is still unclear why the thyroid phenotype is heterogeneous, and why some patients have primary or secondary thyroid dysfunction.


All adult patients had high plasma C3C levels, and the girl had low C4 levels, as well as a low total T-cell count. The adult women had elevated IgG and IgA levels (21). Immunoglobulin levels were normal in the boy, except for elevated IgE, indicating atopy. He also had normal blood cells count, with decrease in the absolute lymphocyte count 6 weeks after leptin was initiated, from 3.5 × 103 µL−1 to 2.9 × 103 µL−1. By flow cytometry, we determined that the decrease in lymphocytes corresponded to decreases in CD3, CD4 and CD19 cells.

In the boy, lymphocyte proliferative response to mitogens phytohaemagglutinin, concanavalin A, pokeweed, tetanus and candida antigens was normal at baseline, except for tetanus. Two and six weeks after treatment, responses increased significantly for all substances, except for tetanus antigen (40). Therefore, leptin enhanced T-cell responsiveness, even in a normal setting.

Brain structure and function

Eighteen months of leptin replacement increased grey matter concentration in three brain regions of the adults: the anterior cingulate gyrus, parietal lobe and medial cerebellum (41), which are implicated in neural circuits regulating hunger and satiation. Unpublished results show that annual withholding of replacement for several weeks reverses this effect in the same brain structures, and treatment re-initiation partially restores grey matter.

In functional studies, leptin replacement reduced activation of regions linked to hunger (insula, parietal and temporal cortex) and enhanced activation of regions linked to inhibition and satiety (prefrontal cortex), as well as the cerebellum. These results show that leptin has extra-hypothalamic effects in the regulation of food intake (42).

Procognitive effects of leptin were demonstrated in the boy, who presented improvements of several subtests of the Differential Ability Scale, a measure of general verbal and non-verbal functioning, and of selected subtests from the neuropsychological assessment (NEPSY), a measure of neuropsychological functioning in children (17). At baseline, the adult patients did not reach scores compatible with anxiety or depression on the Hamilton scale, and no changes during treatment were observed. Nevertheless, we noted that the patients' behaviour changed from very docile and infantile to assertive and adult-like, within 2 weeks of the onset of leptin treatment, before weight loss occurred (16).


  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References

Leptin replacement therapy is currently the only successful hormonal treatment for a monogenic form of obesity. We summarize here the phenotype and the effects of leptin replacement in a cohort of genetically leptin-deficient Turkish patients (Table 1). In these 10 years, we observed that leptin is a pleiotropic hormone, important not only for the regulation of food intake and body composition, but also with crucial effects on the lipid and glucose metabolism, on the gonadal, adrenal, somatotropic and thyroid axes, on sympathetic tone, on biomarkers of cardiovascular disease, on immunity and on brain structure and function. New findings on the roles of leptin on neurodegenerative diseases (43,44) support the hypothesis that leptin has neuroplastic and neurotrophic effects, and could be useful for treating or preventing such diseases. Furthermore, leptin can be a potential anti-lipotoxic agent in a clinical setting, such as for preventing transplanted islet cell graft failure (45) and for treating non-alcoholic steatohepatitis (46).

Table 1.  Summary of the effects of leptin replacement therapy
  • *

    Alterations assessed exclusively in patient D.

Endocrine effectsReversal of type 2 diabetes
Increase in insulin sensitivity; decrease in insulin secretion and in hepatic extraction
Reversal of hypogonadotropic hypogonadism
Increase in 24-h cortisolemia, with changes in rhythmicity towards a more regular pattern
Increase in insulin-like growth factor binding protein (IGFBP1) and insulin-like growth factor binding protein (IGFBP2)
Maintenance of adequate growth velocity*
Regulation of the thyroid-stimulating hormone (TSH) rhythmicity
Body compositionWeight loss, mostly fat – up to 54% of initial body weight
Brain and behaviourDecrease in caloric intake, with changes in food preference
Increase in physical activity
Increase in grey matter concentration
Activation of brain areas involved with satiety and inhibition of areas involved with hunger
Increase in cognitive development*
Changes from docile and infantile to assertive and adult-like behaviour
Metabolic effectsLower decrease in energy expenditure after weight loss
Decrease in triglycerides and increase in high-density lipoprotein cholesterol (HDL-c)
Inhibition of lipogenesis and stimulation of lipolysis
Biomarkers of inflammation, coagulation, fibrinolysis and platelet aggregationLeptin withdrawal: changes towards a decreased state of thrombogenesis and increased fibrinolysis
ImmunityDecrease in the absolute lymphocyte count (CD3, CD4, CD19 cells)*
Increased T-cell responsiveness*

Our results are important not only to guide the treatment of leptin-deficient patients – including those with lipodystrophy syndromes, but also to direct future studies on the usefulness of leptin in treating or preventing other diseases or conditions, such as common obesity, lipodystrophy syndromes, diabetes, hypothalamic amenorrhea, anorexia nervosa, mood and cognitive disorders, immune deficiencies and lipotoxicity.


  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References

We thank Amgen Inc., and Amylin Pharmaceuticals for graciously providing recombinant methionyl human leptin free of charge. We also thank Dr Amhet Yesilyurt for designing the pedigree chart. The preparation of this review was supported by ANU's institutional funds. During the course of this study, Amgen, Inc. and Amylin Pharmaceuticals, Inc. provided recombinant methionyl human leptin. Neither Amgen, Inc. nor Amylin Pharmaceuticals, Inc. contributed to the design, analysis or writing of this study.


  1. Top of page
  2. Summary
  3. Introduction
  4. Leptin deficiency in patients of Pakistani, Egyptian and Austrian backgrounds
  5. Leptin deficiency in Turkish patients
  6. Conclusions
  7. Conflict of Interest Statement
  8. Acknowledgements
  9. References
  • 1
    Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425432.
  • 2
    Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered 1950; 41: 317318.
  • 3
    Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science 1966; 153: 11271128.
  • 4
    Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763770.
  • 5
    Swerdloff RS, Batt RA, Bray GA. Reproductive hormonal function in the genetically obese (ob/ob) mouse. Endocrinology 1976; 98: 13591364.
  • 6
    Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 11851188.
  • 7
    Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 1997; 94: 10231028.
  • 8
    Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005; 174: 31373142.
  • 9
    Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146: 53415349.
  • 10
    Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197207.
  • 11
    Coleman DL, Hummel KP. Effects of parabiosis of normal with genetically diabetic mice. Am J Physiol 1969; 217: 12981304.
  • 12
    Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 1973; 9: 294298.
  • 13
    Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903908.
  • 14
    Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 10931103.
  • 15
    Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, Trussell RA. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 2004; 89: 48214826.
  • 16
    Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong ML. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 2004; 101: 45314536.
  • 17
    Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK, Wong ML, Licinio J. Leptin replacement improves cognitive development. PLoS ONE 2008; 3: e3098.
  • 18
    Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998; 18: 213215.
  • 19
    Mazen I, El-Gammal M, Abdel-Hamid M, Amr K. A novel homozygous missense mutation of the leptin gene (N103K) in an obese Egyptian patient. Mol Genet Metab 2009; 97: 305308.
  • 20
    Fischer-Posovszky P, von Schnurbein J, Moepps B, Lahr G, Strauss G, Barth TF, Kassubek J, Muhleder H, Moller P, Debatin KM, Gierschik P, Wabitsch M. A new missense mutation in the leptin gene causes mild obesity and hypogonadism without affecting T cell responsiveness. J Clin Endocrinol Metab 2010; 95: 28362840.
  • 21
    Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84: 36863695.
  • 22
    Farooqi IS, O'Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89: 980S984S.
  • 23
    Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency [see comments]. N Engl J Med 1999; 341: 879884.
  • 24
    Butler MG, Moore J, Morawiecki A, Nicolson M. Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet 1998; 75: 712.
  • 25
    Ellis KJ, Nicolson M. Leptin levels and body fatness in children: effects of gender, ethnicity, and sexual development. Pediatr Res 1997; 42: 484488.
  • 26
    Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, Chrousos GP, Karp B, Allen C, Flier JS, Gold PW. Human leptin levels are pulsatile and inversely related to pituitary- adrenal function. Nat Med 1997; 3: 575579.
  • 27
    Heymsfield SB, Fong TM, Gantz I, Erondu N. Fat and energy partitioning: longitudinal observations in leptin-treated adults homozygous for a Lep mutation. Obesity (Silver Spring) 2006; 14: 258265.
  • 28
    Licinio J, Ribeiro L, Busnello JV, Delibasi T, Thakur S, Elashoff RM, Sharma A, Jardack PM, Depaoli AM, Wong ML. Effects of leptin replacement on macro- and micronutrient preferences. Int J Obes (Lond) 2007; 31: 18591863.
  • 29
    Licinio J, Milane M, Thakur S, Whelan F, Yildiz BO, Delibasi T, de Miranda PB, Ozata M, Bolu E, Depaoli A, Wong ML. Effects of leptin on intake of specific micro- and macronutrients in a woman with leptin gene deficiency studied off and on leptin at stable body weight. Appetite 2007; 49: 594599.
  • 30
    Williamson DA, Ravussin E, Wong ML, Wagner A, Dipaoli A, Caglayan S, Ozata M, Martin C, Walden H, Arnett C, Licinio J. Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite 2005; 45: 7580.
  • 31
    Galgani JE, Greenway FL, Caglayan S, Wong ML, Licinio J, Ravussin E. Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients. J Clin Endocrinol Metab 2010; 95: 851855.
  • 32
    Andreev VP, Paz-Filho G, Wong ML, Licinio J. Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-hour standardized meals: time course of glucose homeostasis in leptin replacement treatment. Horm Metab Res 2009; 41: 142151.
  • 33
    Paz-Filho G, Esposito K, Hurwitz B, Sharma A, Dong C, Andreev V, Delibasi T, Erol H, Ayala A, Wong ML, Licinio J. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am J Physiol Endocrinol Metab 2008; 295: E1401E1408.
  • 34
    Paz-Filho GJ, Ayala A, Esposito K, Erol HK, Delibasi T, Hurwitz BE, Wong ML, Licinio J. Effects of leptin on lipid metabolism. Horm Metab Res 2008; 40: 572574.
  • 35
    Mantzoros CS, Flier JS, Rogol AD. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J Clin Endocrinol Metab 1997; 82: 10661070.
  • 36
    Paz-Filho GJ, Andrews D, Esposito K, Erol HK, Delibasi T, Wong ML, Licinio J. Effects of leptin replacement on risk factors for cardiovascular disease in genetically leptin-deficient subjects. Horm Metab Res 2009; 41: 164167.
  • 37
    Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009; 20: 153162.
  • 38
    Paz-Filho G, Delibasi T, Erol HK, Wong ML, Licinio J. Congenital leptin deficiency and thyroid function. Thyroid Res 2009; 2: 11.
  • 39
    Mantzoros CS, Ozata M, Negrao AB, Ziotopoulou M, Caglayan S, Suchard M, Cogswell RJ, Negro P, Elashoff RM, Liberty V, Wong M-L, Veldhuis JD, Ozdemir IC, Gold PW, Flier JS, Licinio J. Synchronicity of frequently sampled TSH and leptin concentrations in healthy adults and leptin deficient subjects: evidence for possible partial TSH regulation by leptin in humans. J Clin Endocrinol Metab 2001; 86: 32843291.
  • 40
    Paz-Filho GJ, Delibasi T, Erol HK, Wong ML, Licinio J. Cellular immunity before and after leptin replacement therapy. J Pediatr Endocrinol Metab 2009; 22: 10691074.
  • 41
    Matochik JA, London ED, Yildiz BO, Ozata M, Caglayan S, DePaoli AM, Wong ML, Licinio J. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J Clin Endocrinol Metab 2005; 90: 28512854.
  • 42
    Baicy K, London ED, Monterosso J, Wong ML, Delibasi T, Sharma A, Licinio J. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc Natl Acad Sci USA 2007; 104: 1827618279.
  • 43
    Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S. Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 2009; 16: 731740.
  • 44
    Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009; 302: 25652572.
  • 45
    Lee Y, Ravazzola M, Park BH, Bashmakov YK, Orci L, Unger RH. Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin. Diabetes 2007; 56: 22952301.
  • 46
    Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753760.